北陆药业
(300016)
| 流通市值：48.68亿 | | | 总市值：50.37亿 |
| 流通股本：5.62亿 | | | 总股本：5.82亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 320,369,738.33 | 1,205,275,821.64 | 872,684,962.37 | 584,208,873.71 |
| 营业收入 | 320,369,738.33 | 1,205,275,821.64 | 872,684,962.37 | 584,208,873.71 |
| 二、营业总成本 | 279,988,815.02 | 1,155,065,353.55 | 839,914,027.39 | 553,854,245.81 |
| 营业成本 | 171,336,811.23 | 653,176,771.33 | 472,361,615.01 | 309,243,894.14 |
| 税金及附加 | 3,745,144.95 | 15,464,041.36 | 11,210,241.99 | 7,597,441.8 |
| 销售费用 | 60,907,136.02 | 261,516,764.82 | 191,274,741 | 128,352,971.62 |
| 管理费用 | 23,176,042.59 | 92,629,690.14 | 65,518,907.81 | 43,660,638.96 |
| 研发费用 | 15,449,204.98 | 93,390,891.43 | 63,963,081.76 | 39,027,284.47 |
| 财务费用 | 5,374,475.25 | 38,887,194.47 | 35,585,439.82 | 25,972,014.82 |
| 其中:利息费用 | 3,394,425.51 | 39,777,306.72 | 37,194,306.43 | 27,537,146.77 |
| 其中:利息收入 | 1,212,104.13 | 4,288,976.3 | 3,165,047.24 | 2,110,189.04 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 2,845,628.86 | 53,436,304.56 | 5,239,359.21 | -855,712.62 |
| 加:投资收益 | 5,496,941.93 | 8,067,847.7 | 6,744,921.07 | 990,763.49 |
| 资产处置收益 | - | -1,229,172.24 | -1,266,134.62 | -1,266,134.62 |
| 资产减值损失(新) | 1,532,821.38 | -9,137,090.82 | -4,889,852.17 | -2,499,339.52 |
| 信用减值损失(新) | 999,423.38 | -4,202,488.92 | -2,181,030.03 | -1,762,345.3 |
| 其他收益 | 3,647,508.18 | 13,131,876.71 | 9,399,488.38 | 5,573,917.52 |
| 四、营业利润 | 54,903,247.04 | 110,277,745.08 | 45,817,686.82 | 30,535,776.85 |
| 加:营业外收入 | 1,812.2 | 526,452.91 | 447,819.13 | 389,948.31 |
| 减:营业外支出 | 206,943.85 | 2,290,603.75 | 1,280,945.32 | 874,294.37 |
| 五、利润总额 | 54,698,115.39 | 108,513,594.24 | 44,984,560.63 | 30,051,430.79 |
| 减:所得税费用 | 8,543,731.65 | 19,865,522.23 | 5,518,574.84 | 3,114,209.89 |
| 六、净利润 | 46,154,383.74 | 88,648,072.01 | 39,465,985.79 | 26,937,220.9 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 46,154,383.74 | 88,648,072.01 | 39,465,985.79 | 26,937,220.9 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 44,975,808.94 | 92,734,719.39 | 44,176,899.13 | 29,966,924.99 |
| 少数股东损益 | 1,178,574.8 | -4,086,647.38 | -4,710,913.34 | -3,029,704.09 |
| 扣除非经常损益后的净利润 | 39,717,696.41 | 40,057,378.9 | 33,675,826.98 | 29,737,612.39 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.08 | 0.18 | 0.09 | 0.06 |
| (二)稀释每股收益 | 0.08 | 0.18 | - | 0.09 |
| 九、综合收益总额 | 46,154,383.74 | 88,648,072.01 | 39,465,985.79 | 26,937,220.9 |
| 归属于母公司股东的综合收益总额 | 44,975,808.94 | 92,734,719.39 | 44,176,899.13 | 29,966,924.99 |
| 归属于少数股东的综合收益总额 | 1,178,574.8 | -4,086,647.38 | -4,710,913.34 | -3,029,704.09 |
| 公告日期 | 2026-04-29 | 2026-04-22 | 2025-10-29 | 2025-08-26 |
| 审计意见(境内) | | 标准无保留意见 | | |